A review published in Genes & Diseases highlights how changes to sugar molecules on cancer cells could help tumors grow, spread, resist treatment, and evade immune attack. Researchers at Shandong Provincial Hospital, affiliated to Shandong First Medical University, examine abnormal sialylation and its potential to guide cancer diagnosis and the development of targeted therapies.
Sialylation is the process of adding sialic acids to sugar chains attached to proteins and fats. These molecules help regulate normal cell communication and biological functions. In cancer, however, their abundance and arrangement can change, altering how tumor cells interact with tissues and the immune system.
The review brings together evidence across solid tumors and blood cancers, including gastric, colorectal, breast, lung, and pancreatic cancers, as well as leukemia and multiple myeloma. It examines two enzyme groups that control this process: sialyltransferases, which add sialic acids, and neuraminidases, which remove them. Disruption of this balance can influence tumor behavior.
One important mechanism involves immune evasion. Sialic acids displayed on tumor cells can engage receptors called Siglecs on immune cells, sending signals that suppress anticancer responses. This interaction creates opportunities for therapies designed to interrupt those signals or remove sialic acids from tumor surfaces.
The article also explores links between abnormal sialylation and drug resistance. Studies reviewed suggest that changes in the enzyme ST6Gal1 can affect responses to treatments such as trastuzumab in gastric cancer. Other findings connect altered sialylation with resistance in colorectal cancer and leukemia, supporting further investigation into combinations with existing treatments.
Potential approaches include sialyltransferase inhibitors, antibodies targeting Siglecs, and antibody-sialidase conjugates that direct sugar-removing enzymes towards cancer cells. Engineered immune cells and proteins that recruit T cells while modifying tumor surface sugars also show promise in experimental models.
Beyond treatment, sialylation patterns could provide biomarkers for detecting cancer, assessing disease progression, or predicting treatment response. The review describes analytical technologies, including mass spectrometry and molecular imaging approaches, that could help researchers identify these patterns more precisely.
Important challenges remain. Sialylation also supports healthy tissues, and broad inhibition has caused liver and kidney dysfunction in animal studies. Its effects differ between cancers, with some findings suggesting protective roles. Developing selective treatments and validating biomarkers are therefore essential.
Source:
Journal reference:
Kong, R., et al. (2026) Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics, Genes & Diseases. DOI: 10.1016/j.gendis.2026.102080. https://www.sciencedirect.com/science/article/pii/S2352304226000528?via%3Dihub